Zobrazeno 1 - 10
of 241
pro vyhledávání: '"PSMA-617"'
Autor:
Marco Nicola Iannone, Silvia Valtorta, Stefano Stucchi, Stefano Altomonte, Elia Anna Turolla, Elisa Vino, Paolo Rainone, Valentina Zecca, Alessia Lo Dico, Marco Maspero, Mariangela Figini, Matteo Bellone, Samuele Ciceri, Diego Colombo, Clizia Chinello, Lisa Pagani, Rosa Maria Moresco, Sergio Todde, Patrizia Ferraboschi
Publikováno v:
EJNMMI Radiopharmacy and Chemistry, Vol 9, Iss 1, Pp 1-30 (2024)
Abstract Background In the last decade the development of new PSMA-ligand based radiopharmaceuticals for the imaging and therapy of prostate cancer has been a highly active and important area of research. The most promising derivative in terms of int
Externí odkaz:
https://doaj.org/article/a91d26a7184b4828a1736c39a7f40a60
Autor:
Tachatumvitoon, Kalapaphuk a, Preuksarattanawut, Charasphat b, c, Tippayamontri, Thititip d, Khomein, Piyachai e, ⁎
Publikováno v:
In Bioorganic & Medicinal Chemistry 1 February 2025 118
Publikováno v:
Разработка и регистрация лекарственных средств, Vol 12, Iss 4, Pp 27-39 (2023)
Introduction. The use of radiopharmaceuticals for targeted radionuclide therapy (TRT), the efficacy of which was established during clinical trials, is safe and effective for various pathological conditions, including cancer. The main feature of ther
Externí odkaz:
https://doaj.org/article/92b1f8adb25e438b91354b1363517f28
Autor:
Rien Ritawidya, Hendris Wongso, Nurmaya Effendi, Anung Pujiyanto, Wening Lestari, Herlan Setiawan, Titis Sekar Humani
Publikováno v:
Advanced Pharmaceutical Bulletin, Vol 13, Iss 4, Pp 701-711 (2023)
Prostate-specific membrane antigen (PSMA) represents a promising target for PSMA-overexpressing diseases, especially prostate cancer-a common type of cancer among men worldwide. In response to the challenges in tackling prostate cancers, several prom
Externí odkaz:
https://doaj.org/article/e7563736b1504f889fdfab272e566029
Publikováno v:
Asia Oceania Journal of Nuclear Medicine and Biology, Vol 12, Iss 1, Pp 43-45 (2024)
68Ga-PSMA PET/CT has been routinely utilized in patients with intermediate to high-risk category prostate carcinoma for staging, biochemical recurrence and before planning the PSMA radioligand therapy (RLT). 177Lu-PSMA RLT has also been approved by F
Externí odkaz:
https://doaj.org/article/4a4291c160a545f982c85f059ab5856a
Publikováno v:
Регуляторные исследования и экспертиза лекарственных средств, Vol 12, Iss 4, Pp 455-467 (2022)
Radiochemical purity (RCP) is one of the key quality criteria for radiopharmaceuticals (RPs) used in clinical practice. The results of RCP measurements depend on the analytical technique, as well as detection parameters, which are specific to a parti
Externí odkaz:
https://doaj.org/article/2928a79c68924745a4d55f3beb923296
Autor:
Marjolein Verhoeven, Eline A. M. Ruigrok, Geert J. L. H. van Leenders, Lilian van den Brink, Hayri E. Balcioglu, Wytske M. van Weerden, Simone U. Dalm
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionCentral to targeted radionuclide imaging and therapy of prostate cancer (PCa) are prostate-specific membrane antigen (PSMA)-targeting radiopharmaceuticals. Gastrin-releasing peptide receptor (GRPR) targeting has been proposed as a potenti
Externí odkaz:
https://doaj.org/article/accb1ad6d1da457fba2d6b246b633125
Autor:
Harun Taş, Gábor Bakos, Ulrike Bauder-Wüst, Martin Schäfer, Yvonne Remde, Mareike Roscher, Martina Benešová-Schäfer
Publikováno v:
Pharmaceuticals, Vol 17, Iss 4, p 513 (2024)
[177Lu]Lu-PSMA-617 has recently been successfully approved by the FDA, the MHRA, Health Canada and the EMA as Pluvicto®. However, salivary gland (SG) and kidney toxicities account for its main dose-limiting side-effects, while its corresponding upta
Externí odkaz:
https://doaj.org/article/9448b88781b44e8394308743e05b9eb9
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.